Follow the people · Insider
Eric Warren
Eric Warren files insider transactions with the SEC as a chief commercial officer of Mineralys Therapeutics (MLYS). We hold 3 disclosed purchases and sales filed since 16 March 2022, 3 of them in the last 90 days.
- Files forMLYS
- Disclosed buys and sells3 in all, 3 in the last 90 days
- Last disclosure25 August 2026
Positions held
2 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 26 June 2026 — 21 August 2026Chief Commercial Officer · Mineralys Therapeutics (MLYS)9 Form 4 lines · source: SEC Form 4
- Filed 14 March 2022 — 17 April 2025Chief Commercial Officer · Esperion Therapeutics (ESPR)35 Form 4 lines · source: SEC Form 4
Everything they disclosed
44 entries, newest first — one per disclosure report, one per Form 4 line- exercised options over 7,437 shares of Mineralys TherapeuticsSEC Form 425 August 2026Common Stock · traded 21 August 2026 · filed 25 August 2026
- ▼ sold on the open market 7,437 shares of Mineralys TherapeuticsSEC Form 425 August 2026Common Stock · traded 21 August 2026 · filed 25 August 2026
- exercised options over 7,437 shares of Mineralys Therapeutics (a derivative holding)SEC Form 425 August 2026Stock Option · traded 21 August 2026 · filed 25 August 2026
- exercised options over 7,438 shares of Mineralys TherapeuticsSEC Form 423 July 2026Common Stock · traded 21 July 2026 · filed 23 July 2026
- ▼ sold on the open market 7,438 shares of Mineralys TherapeuticsSEC Form 423 July 2026Common Stock · traded 21 July 2026 · filed 23 July 2026
- exercised options over 7,438 shares of Mineralys Therapeutics (a derivative holding)SEC Form 423 July 2026Stock Option · traded 21 July 2026 · filed 23 July 2026
- exercised options over 104,124 shares of Mineralys TherapeuticsSEC Form 430 June 2026Common Stock · traded 26 June 2026 · filed 30 June 2026
- ▼ sold on the open market 104,124 shares of Mineralys TherapeuticsSEC Form 430 June 2026Common Stock · traded 26 June 2026 · filed 30 June 2026
- exercised options over 104,124 shares of Mineralys Therapeutics (a derivative holding)SEC Form 430 June 2026Stock Option · traded 26 June 2026 · filed 30 June 2026
- ▼ sold on the open market 108 shares of Esperion TherapeuticsSEC Form 421 April 2025Common Stock · traded 17 April 2025 · filed 21 April 2025
- ▼ sold on the open market 2,433 shares of Esperion TherapeuticsSEC Form 419 March 2025Common Stock · traded 18 March 2025 · filed 19 March 2025
- was granted 191,000 shares of Esperion Therapeutics (a derivative holding)SEC Form 417 March 2025Stock Option (right to buy) · traded 14 March 2025 · filed 17 March 2025
- was granted 213,000 shares of Esperion TherapeuticsSEC Form 417 March 2025Common Stock · traded 14 March 2025 · filed 17 March 2025
- ▼ sold on the open market 239 shares of Esperion TherapeuticsSEC Form 420 February 2025Common Stock · traded 19 February 2025 · filed 20 February 2025
- ▼ sold on the open market 123 shares of Esperion TherapeuticsSEC Form 421 January 2025Common Stock · traded 17 January 2025 · filed 21 January 2025
- ▼ sold on the open market 2,234 shares of Esperion TherapeuticsSEC Form 418 December 2024Common Stock · traded 17 December 2024 · filed 18 December 2024
- ▼ sold on the open market 197 shares of Esperion TherapeuticsSEC Form 420 November 2024Common Stock · traded 19 November 2024 · filed 20 November 2024
- ▼ sold on the open market 107 shares of Esperion TherapeuticsSEC Form 418 October 2024Common Stock · traded 17 October 2024 · filed 18 October 2024
- ▼ sold on the open market 2,608 shares of Esperion TherapeuticsSEC Form 418 September 2024Common Stock · traded 17 September 2024 · filed 18 September 2024
- ▼ sold on the open market 211 shares of Esperion TherapeuticsSEC Form 420 August 2024Common Stock · traded 19 August 2024 · filed 20 August 2024
- ▼ sold on the open market 108 shares of Esperion TherapeuticsSEC Form 419 July 2024Common Stock · traded 17 July 2024 · filed 19 July 2024
- ▼ sold on the open market 2,540 shares of Esperion TherapeuticsSEC Form 420 June 2024Common Stock · traded 18 June 2024 · filed 20 June 2024
- ▼ sold on the open market 192 shares of Esperion TherapeuticsSEC Form 420 May 2024Common Stock · traded 17 May 2024 · filed 20 May 2024
- was granted 150,000 shares of Esperion Therapeutics (a derivative holding)SEC Form 415 March 2024Stock Option (right to buy) · traded 14 March 2024 · filed 15 March 2024
- was granted 100,000 shares of Esperion TherapeuticsSEC Form 415 March 2024Common Stock · traded 14 March 2024 · filed 15 March 2024
- ▼ sold on the open market 742 shares of Esperion TherapeuticsSEC Form 421 September 2023Common Stock · traded 20 September 2023 · filed 21 September 2023
- ▼ sold on the open market 243 shares of Esperion TherapeuticsSEC Form 421 August 2023Common Stock · traded 18 August 2023 · filed 21 August 2023
- ▼ sold on the open market 106 shares of Esperion TherapeuticsSEC Form 420 July 2023Common Stock · traded 19 July 2023 · filed 20 July 2023
- ▼ sold on the open market 603 shares of Esperion TherapeuticsSEC Form 422 June 2023Common Stock · traded 21 June 2023 · filed 22 June 2023
- ▼ sold on the open market 219 shares of Esperion TherapeuticsSEC Form 418 May 2023Common Stock · traded 17 May 2023 · filed 18 May 2023
- ▼ sold on the open market 115 shares of Esperion TherapeuticsSEC Form 420 April 2023Common Stock · traded 19 April 2023 · filed 20 April 2023
- ▼ sold on the open market 526 shares of Esperion TherapeuticsSEC Form 420 March 2023Common Stock · traded 17 March 2023 · filed 20 March 2023
- was granted 94,500 shares of Esperion Therapeutics (a derivative holding)SEC Form 415 March 2023Stock Option (right to buy) · traded 14 March 2023 · filed 15 March 2023
- was granted 22,300 shares of Esperion TherapeuticsSEC Form 415 March 2023Common Stock · traded 14 March 2023 · filed 15 March 2023
- ▼ sold on the open market 5,090 shares of Esperion TherapeuticsSEC Form 48 March 2023Common Stock · traded 7 March 2023 · filed 8 March 2023
- ▼ sold on the open market 107 shares of Esperion TherapeuticsSEC Form 419 October 2022Common Stock · traded 18 October 2022 · filed 19 October 2022
- ▼ sold on the open market 255 shares of Esperion TherapeuticsSEC Form 420 September 2022Common Stock · traded 19 September 2022 · filed 20 September 2022
- ▲ bought on the open market 1,000 shares of Esperion TherapeuticsSEC Form 431 August 2022Common Stock · traded 31 August 2022 · filed 31 August 2022
- ▼ sold on the open market 199 shares of Esperion TherapeuticsSEC Form 418 August 2022Common Stock · traded 17 August 2022 · filed 18 August 2022
- ▼ sold on the open market 431 shares of Esperion TherapeuticsSEC Form 420 July 2022Common Stock · traded 19 July 2022 · filed 20 July 2022
- ▼ sold on the open market 256 shares of Esperion TherapeuticsSEC Form 421 June 2022Common Stock · traded 17 June 2022 · filed 21 June 2022
- was granted 52,000 shares of Esperion Therapeutics (a derivative holding)SEC Form 49 June 2022Stock Option (right to buy) · traded 7 June 2022 · filed 9 June 2022
- ▼ sold on the open market 196 shares of Esperion TherapeuticsSEC Form 418 May 2022Common Stock · traded 17 May 2022 · filed 18 May 2022
- was granted 13,000 shares of Esperion TherapeuticsSEC Form 416 March 2022Common Stock · traded 14 March 2022 · filed 16 March 2022
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.